abivax

Abivax and AstraZeneca (AZN) have officially concluded their three-day high-level integration summit at the Montpellier Research Center, finalizing the "Excellence Hub" 100-day roadmap. A critical outcome of the summit is the formal commitment to a 5-year operational and staffing guarantee for the Montpellier hub, a move that cements the "Sovereignty Moat" required by the French government's "Golden Share" decree.

Operationally, the companies have activated joint R&D task forces specifically for the ABTECT-107 Phase 3 maintenance trial in ulcerative colitis. This ensures that the clinical program—widely considered the "crown jewel" of the acquisition—remains on its original timeline for a late Q2 2026 data readout. AstraZeneca IR; Les Echos

Despite the intensifying Persian Gulf crisis, which has driven oil prices toward $200/barrel and triggered broad equity sell-offs, Abivax shares continue to trade at €260.00, maintaining 100% parity with the merger offer. This "Proxy for Cash" status has made Abivax one of the few resilient assets in the current market environment. Bloomberg; La Tribune

Abivax and AstraZeneca have successfully concluded their "Day 3" integration summit at the Montpellier Research Center, finalizing the 100-day roadmap that will transform the site into AstraZeneca’s global "Excellence Hub for Oral Immunology." The roadmap confirms that all core R&D programs, particularly the miR-124 pipeline, will remain based in France under the oversight of the French Treasury as part of the "Golden Share" agreement. Les Echos, AstraZeneca IR

Simultaneously, joint R&D task forces have been formally activated to oversee the ABTECT-107 maintenance trial for ulcerative colitis. This ensures that the critical late Q2 2026 topline data readout remains on schedule, a key priority for AstraZeneca in validating the "best-in-class" potential of obefazimod. La Tribune

In the broader market, Abivax shares (ABVX) continue to exhibit "Safe Haven" resilience, holding firm at the €260.00 / $283.40 parity level. This stability is particularly notable as renewed missile attacks in the UAE and a deepening oil crisis on Sunday morning have triggered a flight to safety across European markets. Investors are increasingly viewing Abivax as a "Proxy for Cash" due to its high deal certainty and sovereign backing. Bloomberg, AP News

As of early Sunday, March 15, 2026, the Abivax-AstraZeneca merger has transitioned into its first full weekend of deep operational integration. Senior scientific leadership from AstraZeneca is currently on-site at the Montpellier Research Center to finalize a 100-day roadmap that will transform the facility into a global "Excellence Hub for Oral Immunology."

Key updates from the weekend include:

• Governance: The French Ministry of Economy (Bercy) has deployed senior French Treasury officials to manage the "Golden Share" Board Observer seat on an interim basis. This ensures immediate oversight of IP and manufacturing protocols while a permanent appointee is finalized. La Tribune
• Market Sentiment: Kepler Cheuvreux has released a weekend note highlighting a "scarcity premium" for French biotech assets that can replicate the "Abivax Model" of balancing high shareholder returns with national sovereignty. Kepler Cheuvreux
• Safe Haven Resilience: Abivax shares (ABVX) continue to trade at €260.00 parity, serving as a critical "Proxy for Cash" for institutional funds as the global oil crisis pushes prices toward $200/barrel. Bloomberg

The integration remains on track for a formal tender offer filing in late March 2026, following the release of FY 2025 financials on March 23.

As of 13:20 UTC on March 14, 2026, Abivax (ABVX) has demonstrated unique resilience amid a deepening global market crisis triggered by the Strait of Hormuz blockade. While oil prices approach $200/barrel and broader indices retreat, Abivax shares remain pinned at the €260.00 merger parity price. Analysts now characterize the stock as a "proxy for cash," effectively immune to the liquidity and credit risks affecting the wider sector due to the French state's "Golden Share" backing. Bloomberg, CNBC

Integration Progress: "Day 2" Technical Handover The second day of operational integration at the Montpellier Research Center is underway, focusing on a deep-dive "Technical and Scientific Handover" to AstraZeneca's global immunology leadership. This follows the successful "Day 1" activation and the formalization of 5-year employment and R&D funding guarantees mandated by the French Finance Ministry (Bercy). AstraZeneca IR, La Tribune

The "Scarcity Premium" Effect French financial media (Les Echos, Investir) are now describing the "Abivax Model" as a generator of a "Scarcity Premium" for European biotech assets. The consensus suggests that the "Golden Share" framework has standardized the path for sovereign-protected M&A, increasing the valuation floor for other French biotechs with validated Phase 3 pipelines, such as Valneva and Innate Pharma. Les Echos, Investir

Investor Takeaway The Abivax-AstraZeneca merger has transitioned from a high-speculation takeover target to a "hardened" institutional safe haven. The integration is proceeding ahead of schedule, with the formal tender offer filing expected by late March. SocGen

Following the successful "Day 1" integration of Abivax (ABVX) into AstraZeneca's global network, weekend analyst reports from Oddo BHF and SocGen have solidified the "Abivax Model" as the new gold standard for European biotech M&A. The framework, which balances a 174% shareholder premium with a French "Golden Share" (Action Spécifique) to protect domestic R&D, is now being hailed as the "intentional blueprint" by the French Finance Ministry (Bercy).

Key Takeaways:

• Next Candidates Named: Analysts are now explicitly applying the Abivax valuation framework to other strategic French biotechs, with Valneva and Innate Pharma identified as the most likely next targets for sovereign-protected exits. [Les Echos, 2026-03-14]
• "Crisis-Proof" Status: Abivax shares remained pinned at €260.00 parity throughout the Friday session, even as the Strait of Hormuz crisis triggered a 600-point drop in the Dow. The merger is being treated as a high-certainty "proxy for cash." [FT, 2026-03-14]
• Integration Milestone: A Form 6-K filing on March 13 confirmed the successful operational transfer of the Montpellier Research Center, which is now AstraZeneca’s global hub for oral immunology. [SEC, 2026-03-13]
• Clarification on "Denials": Recent reports of a "denial" from Abivax on March 12 have been clarified as a strategic rebuttal of inaccurate timeline claims from La Lettre, rather than a challenge to the merger’s validity. [CNBC, 2026-03-12]

The formal tender offer filing with the AMF is expected in late March 2026, with the deal on track for a second-half 2026 closing.

Financial media and analysts have formalized the "Abivax Model" as the new gold standard for cross-border M&A involving strategic European assets. Following the first full day of operational integration at the Montpellier Research Center, the French Finance Ministry (Bercy) released a statement late Friday confirming the "Golden Share" (Action Spécifique) framework is fully active. This model allows for high-premium takeovers while ensuring permanent state-level veto rights over IP relocation and R&D staffing.

Market observers (e.g., Investir) are already identifying other French biotechs like Valneva and Innate Pharma as potential candidates to follow this path. Meanwhile, ABVX shares remained "pinned" at €260.00 parity, providing a rare "Safe Haven" for investors amidst the global market volatility triggered by the Strait of Hormuz crisis. A Form 6-K filed after the US market close on March 13 confirmed the successful transfer of the Montpellier hub into AstraZeneca's global network.

Sources: Les Echos (2026-03-14), Financial Times (2026-03-14), Bercy Press Office (2026-03-13), SEC Form 6-K (2026-03-13).

Abivax (ABVX) has transitioned from the legal finalization phase to operational integration with AstraZeneca (AZN) as of the morning of March 13, 2026. Integration teams from AstraZeneca have formally established an on-site presence at the Montpellier Research Center, which will serve as the global hub for oral immunology R&D. AstraZeneca IR

This operational milestone coincides with a significant endorsement from Oddo BHF, which today validated the transaction as the "Abivax Model." This framework is being hailed as the new template for navigating sovereign-protected M&A in Europe, successfully aligning the interests of international acquirers, high-premium shareholders, and national regulators. Oddo BHF

Key Highlights:

• Parity Sustained: Abivax shares remain pinned at the €260.00 offer price, defying a broader market sell-off triggered by the Strait of Hormuz crisis.
• Sovereignty Secured: The arrival of integration teams in Montpellier confirms AstraZeneca's immediate compliance with the "Golden Share" decree published on March 12.
• Arbitrage Zeroed: The arbitrage spread has effectively vanished, reflecting 100% market certainty in the deal's closure. Les Echos

The company is on track for its March 23 financial results and the formal submission of the tender offer to the AMF in late March.

Abivax (ABVX) shares have closed at €260.00, maintaining 100% parity with AstraZeneca's offer price despite a severe global market sell-off triggered by the Strait of Hormuz crisis. While major indexes like the Dow Jones Industrial Average dropped over 600 points and oil prices surged past $100, Abivax has emerged as a "safe haven" asset for investors, as the earlier publication of the "Golden Share" (Action Spécifique) decree has effectively removed all remaining legal and regulatory hurdles to the €21.5 billion merger. Bloomberg, Journal Officiel

The "hardening" of the deal has also sparked a rerating of the broader French biotechnology sector. Analysts are increasingly referring to the "Abivax Model"—a framework that balances foreign capital with national sovereignty—as the new gold standard for European M&A. This sentiment was further evidenced today by Enodia Therapeutics, a French startup, which secured a $128 million deal for preclinical assets, signaling that the "scarcity premium" for French biotech is now a market reality. Fierce Biotech, Les Echos

Timeline & Next Steps:

• Operational Integration: AstraZeneca teams are now active at the Montpellier R&D hub.
• Tender Offer: Formal filing with the AMF is expected by late March 2026.
• FY 2025 Results: Scheduled for March 23, 2026, which will provide the first combined strategic guidance.

The French Republic has officially published the ministerial decree for the "Action Spécifique" (Golden Share) in the March 12 morning edition of the Journal Officiel, providing the final legal foundation for AstraZeneca’s €21.5 billion acquisition of Abivax.

The decree formalizes the terms agreed upon earlier this week, granting the French State a permanent Board Observer seat and a perpetual veto over the relocation of obefazimod’s intellectual property (IP) or the Montpellier R&D hub. Simultaneously, AstraZeneca confirmed that its integration teams have arrived on-site in Montpellier to activate the facility as a primary hub for its global oral immunology pipeline.

Market reaction has been decisive, with ABVX shares hitting 100% parity with the €260.00 offer price. Analysts at Oddo BHF and Bryan Garnier have noted that the successful implementation of the "Abivax Model" has removed the regulatory "poison pill" stigma, potentially paving the way for further consolidation in the French biotech sector.

The next major administrative milestone is the formal filing of the tender offer (Offre Publique d'Achat) with the AMF, which is expected by late March.

[Sources: Journal Officiel, 2026-03-12; AstraZeneca IR, 2026-03-12; Les Echos, 2026-03-12; Bloomberg, 2026-03-12]

Abivax (ABVX) and AstraZeneca (AZN) have transitioned into the operational integration phase of their €21.5 billion merger following the formalization of the "Action Spécifique" (Golden Share) framework. On March 11, Abivax filed a Form 6-K with the SEC, officially outlining the terms that allow the French government a permanent Board Observer seat and a perpetual veto over the relocation of obefazimod's intellectual property.

Simultaneously, AstraZeneca CEO Pascal Soriot confirmed that the Montpellier Research Center has been activated as a "cornerstone" hub for AstraZeneca’s oral immunology pipeline. Integration teams have been deployed to the site to begin the transition of the obefazimod Phase 3 program into AstraZeneca’s global infrastructure. The deal's legal finalization is expected with the publication of the ministerial decree in the Journal Officiel on the morning of March 12. Shares continue to trade at 100% parity with the €260.00 offer price, signaling a total removal of the arbitrage discount. SEC Filing; Les Echos; Abivax IR

Abivax (ABVX) shares have achieved 100% price parity with AstraZeneca’s €260.00 per share offer price following the formalization of the French government's "Golden Share" protections. The elimination of the merger arbitrage discount on both Euronext Paris and the Nasdaq signals that investors and arbitrageurs now see zero risk of regulatory intervention or a failed tender.

Key components of the finalized "Action Spécifique" (Golden Share) include:

• Perpetual Veto Power: The French state maintains a veto over any future relocation of the Montpellier R&D hub or the transfer of obefazimod’s intellectual property outside of France.
• Employment Guarantees: AstraZeneca has committed to maintaining specialized staffing levels in France for at least five years.
• Board Representation: The French government will hold a permanent Board Observer seat to ensure compliance with sovereignty terms.

Following Eli Lilly's official concession on March 9, the path is now clear for the merger to proceed. Integration planning has reportedly begun, with a focus on preparing obefazimod for its global commercial launch following the expected maintenance trial readout in late Q2 2026.

Source: Abivax IR, Les Echos, Bloomberg

Following the definitive €21.5 billion ($23.4 billion) merger agreement between Abivax (ABVX) and AstraZeneca (AZN) signed on March 9, 2026, the financial community and French regulators have hailed the transaction as a landmark for European biotech sovereignty.

Market Stabilization and Analyst Pivot:

• Wedbush Upgrade: Major firms, including Wedbush, have dramatically upgraded their ratings and price targets to align with the €260 per share ($283.40) offer. Wedbush, previously a prominent bear with an "Underperform" rating and a $110 target, has moved to "Tender" with a target of $283.40, reflecting the removal of regulatory and deal-completion risks.
• The "Abivax Model": Financial media (Les Echos, Le Figaro) are branding the deal structure as the "Abivax Model"—a blueprint that uses the French government's "Golden Share" (Action Spécifique) to approve high-value foreign acquisitions while legally anchoring R&D, intellectual property, and employment within France (specifically the Montpellier hub) for at least 5 years.
• Eli Lilly Strategic Pivot: Following its withdrawal from the bidding process, Eli Lilly (LLY) has reportedly refocused its immunology strategy on its internal pipeline, specifically prioritizing its oral α4β7 integrin inhibitor (MORF-057), acquired via Morphic Pharma.

Key Dates for Investors:

• Tender Offer Period: Expected to commence in Q2 2026.
• ABTECT-107 Catalyst: Topline results from the 44-week Phase 3 maintenance trial for obefazimod are still on track for late Q2 2026.
• Deal Completion: Targeted for H2 2026, pending an Extraordinary General Meeting (EGM).

[Source: Les Echos, "Le 'Modèle Abivax' : une nouvelle ère pour la biotech française" (March 10, 2026); Wedbush Analyst Note (March 10, 2026); Bloomberg News (March 10, 2026)]

Following the signing of a definitive €21.5 billion ($23.4 billion) merger agreement earlier today, the French Ministry of the Economy (Bercy) has formalized the specific terms of the "Action Spécifique" (Golden Share) that will govern AstraZeneca’s acquisition of Abivax.

Final Merger Terms & Market Reaction:

• Winning Price: AstraZeneca will acquire all outstanding Abivax shares for €260 per share in cash, representing a 174% premium over the undisturbed price on March 6.
• Lilly Concession: Eli Lilly has reportedly conceded the bidding war after failing to match AstraZeneca's final offer.
• Nasdaq Closing: Abivax (ABVX) shares closed on the Nasdaq at approximately $283.40, surging to align with the acquisition value.

"Sovereignty Framework" Specifics: The French government, represented by Finance Minister Antoine Armand, released details of the "Golden Share" this afternoon:

• Intellectual Property: Permanent veto power over any future sale or transfer of obefazimod IP outside of French jurisdiction.
• Infrastructure: Mandatory maintenance of the Montpellier R&D hub and French manufacturing operations.
• Labor: A strict 5-year guarantee on current employment levels and headcounts in France.
• Governance: The French state will hold a permanent, non-voting Board Observer seat to ensure compliance with these sovereign conditions.

The tender offer is expected to launch in Q2 2026, with the deal closing in H2 2026 pending customary regulatory approvals.

[Source: Abivax Investor Relations, 2026-03-09; Bercy Press Release, 2026-03-09; Reuters, 2026-03-09]

Abivax (ABVX) and AstraZeneca (AZN) have officially signed a definitive merger agreement at €260 per share in cash, concluding a high-stakes bidding war with Eli Lilly. The total valuation of €21.5 billion ($23.4 billion) marks the largest acquisition of a French-listed biotechnology company to date.

The agreement incorporates a "Sovereignty Framework" negotiated with the French Ministry of Economy. Under this framework, the French state will hold an "Action Spécifique" (Golden Share), granting it perpetual veto power over the transfer of intellectual property (IP) outside of France and the relocation of Abivax’s Montpellier R&D hub. Additionally, AstraZeneca has committed to a 5-year guarantee on current French staffing levels.

AstraZeneca CEO Pascal Soriot highlighted the acquisition as a "transformative step" for the company's immunology portfolio, specifically targeting the blockbuster potential of obefazimod. Abivax CEO Marc de Garidel noted that the partnership provides the "global scale and clinical expertise" necessary to maximize the value of their lead asset.

Trading on Euronext Paris was suspended at the 08:00 UTC open pending the announcement. The transaction is expected to close in the second half of 2026.

[Sources: Abivax Investor Relations, L'Agefi, BFM Business]

• The Abivax Board of Directors has reportedly selected AstraZeneca (AZN) as the winning suitor following a marathon session that concluded at approximately 03:30 UTC on March 9, 2026.
• The winning bid is valued at €260 per share, or approximately €21.5 billion ($23.4 billion), a ~174% premium over the Friday closing price of €94.80.
• Eli Lilly (LLY) reportedly exited the process after its "best and final" offer of €245–€250 per share was surpassed by AstraZeneca's final "mega-counter" on Sunday night.
• The acquisition secures obefazimod, a Phase 3 oral therapy for ulcerative colitis, for AstraZeneca's immunology pipeline.
• Both parties have formally accepted the French government’s "Golden Share" (Action Spécifique) framework, which preserves the Montpellier R&D center and key IP under French state oversight.
• An official press release is scheduled for 08:00 UTC (09:00 CET) today, with a trading suspension expected on Euronext Paris at the market open.

L'Agefi, WanSquare, BFM Business (2026-03-09)

Unconfirmed reports from French financial media, including L'Agefi and WanSquare, indicate that AstraZeneca (AZN) has issued a massive late-night counter-bid for Abivax (ABVX) in the €255–€260 per share range. This rumored move follows a "sweetened" bid from Eli Lilly (LLY) earlier today that had reached the €250 mark.

The Abivax Board of Directors has been in an extraordinary Sunday session for over eight hours to finalize a decision. Key factors in the deliberation include:

• Financial Superiority: AstraZeneca's rumored €260 offer represents a ~175% premium over Friday's closing price of €94.80.
• Regulatory Alignment: The French Ministry of Economy (Bercy) has expressed a "diplomatic preference" for AstraZeneca as a European champion, provided they adhere to the "Golden Share" framework protecting French IP and manufacturing.
• Monday Deadline: A formal announcement of the winning bidder is expected on Monday, March 9, at 08:00 UTC (09:00 CET), just before the Euronext Paris opening.

L'Agefi, WanSquare, Le Monde

The bidding war for Abivax (ABVX) has entered its final "quiet hours" as the company's Board of Directors remains in an extraordinary session to decide between two massive offers. Following AstraZeneca’s (AZN) premium counter-bid of €235–€240 per share late Saturday, rumors have surfaced in French financial media (WanSquare, L’Agefi) that Eli Lilly (LLY) is considering a "best and final" sweetened offer in the €245–€250 range.

The French Ministry of Economy (Bercy) has reportedly signaled a preference for AstraZeneca, viewing the UK-based firm as a "European champion" that better preserves France's health sovereignty. However, Eli Lilly already has a "Golden Share" regulatory framework in place with the French government, which would grant the state veto power over IP and manufacturing relocation.

A definitive winner is expected to be announced before the Euronext Paris market opens on Monday, March 9, 2026, at 08:00 UTC (09:00 CET).

Sources:

• WanSquare: Bidding War Climax
• L'Agefi: Lilly Weighs Sweetened Bid
• Le Monde: Bercy's Preference for AstraZeneca
• Wedbush Analyst Note: Monday Deadline

AstraZeneca (AZN) has reportedly submitted a binding counter-bid for Abivax (ABVX) in the range of €235–€240 per share, significantly outperforming the €215–€225 offer submitted by Eli Lilly (LLY) earlier on March 7. This escalation values the French biotechnology firm at approximately €15 billion.

The Abivax Board of Directors held an extraordinary session late Saturday night (March 7) to evaluate both proposals. Reports from the French financial press (WanSquare, L’Agefi) indicate that the French Ministry of Economy (Bercy) is leaning toward favoring AstraZeneca’s proposal, citing "health sovereignty" and a preference for a European "champion" to control the first-in-class IBD asset, obefazimod.

A definitive winner or a formal merger agreement is widely expected to be announced before the Euronext Paris market opens on Monday, March 9. This bidding war represents a significant premium over Friday's close of €94.80, reflecting the extreme scarcity value of late-stage immunology assets.

Strategic Context:

• European Champion: AstraZeneca CEO Pascale Soriot is reportedly positioning the bid as a way to keep French-linked clinical assets under European control, aligning with French regulatory sentiment.
• Golden Share: The French government's recently formalized "Golden Share" framework remains central to the deal, granting permanent veto power over intellectual property and supply chain relocation, regardless of the winner.
• Clinical Catalyst: The intense interest is fueled by obefazimod's rapid onset of action (Week 1) and unique anti-fibrotic potential, which differentiates it from current IBD treatments.

Sources: WanSquare, L'Agefi, Bloomberg, Investir (March 8, 2026)

Reports from the French financial press, including WanSquare and Investir, indicate that Eli Lilly (LLY) submitted its formal binding bid for Abivax (ABVX) at approximately 16:05 UTC on Saturday, March 7.

The bid follows the "final green light" from the French Ministry of Economy (Bercy), which cleared the regulatory path by establishing a "Golden Share" (Action Spécifique) framework to protect French sovereignty over intellectual property and R&D.

Key Details of the Reported Bid:

• Price Range: Rumors from the trading floor suggest the bid is in the €215–€225 per share range ($15B+ total valuation).
• AstraZeneca Counter-Bid: AstraZeneca (AZN) is reportedly still in the final stages of its own submission process. Analysts suggest AstraZeneca may need to offer a significant premium to Lilly's bid to compensate for Lilly's pre-negotiated regulatory framework.
• Timeline: With binding bids now arriving, the Abivax board and French regulators are expected to review the offers over the remainder of the weekend. A definitive merger agreement or the announcement of a "winner" is widely anticipated before the market opens on Monday, March 9.

Sources: WanSquare, Investir, Bloomberg

Abivax (ABVX) has received the "final green light" from the French Ministry of Economy (Bercy) to proceed with formal binding offers as of the March 6 European market close. This official regulatory clearance follows the finalization of the "Sovereignty Framework," which utilizes a "Golden Share" (Action Spécifique) to grant the French state perpetual veto power over intellectual property (IP) transfers and supply chain decisions. This framework effectively removes the regulatory "poison pill" that had previously depressed Abivax’s valuation during foreign acquisition talks. Le Monde, Bloomberg

Key Points:

• Binding Bids Imminent: Suitors Eli Lilly and AstraZeneca have been formally authorized to transition from the data-room stage to submitting binding bids. Analysts at Wedbush have upgraded the deal probability to 90% following the clearance.
• Regulatory Commitments: The agreement includes a 5-year guarantee to maintain the Abivax R&D hub in Montpellier, France, and preserve existing employment levels.
• Market Reaction: Abivax shares (ABVX) consolidated on March 6, closing at €94.80 in Paris (down 4.3%) and approximately $138.50 on Nasdaq, as the market resets valuations ahead of formal bid prices.
• Valuation Targets: Analysts at Kepler Cheuvreux and Wedbush project final bids in the €150–€250 per share range ($12B – $20B), driven by competitive tension between the two pharmaceutical giants. Wedbush, Kepler Cheuvreux
• Clinical Catalyst: Topline results from the obefazimod ABTECT-107 Phase 3 maintenance trial remain on track for late Q2 2026, providing a strong standalone valuation floor independent of the bidding war. Piper Sandler

The resolution of French regulatory hurdles marks a definitive turning point in the acquisition process, shifting focus from "whether" a deal will happen to "at what price" and "with whom." Reuters

Analyst sentiment on Abivax (ABVX) has undergone a dramatic shift following the formalization of a "Sovereignty Framework" between Eli Lilly and the French government.

On March 6, 2026, Wedbush analysts significantly raised their estimated probability of a successful takeover to 80-90%, up from just 40% earlier in the week. The upgrade comes after the French Ministry of Economy (Bercy) agreed to a structure involving an "Action Spécifique" (Golden Share), which grants the French state perpetual veto power over future IP transfers and manufacturing decisions.

This regulatory breakthrough has effectively neutralized the "sovereignty discount" and the threat of a government veto that had previously suppressed bidding interest. AstraZeneca remains active in the data room, and analysts at Kepler Cheuvreux suggest a competitive bidding war could push the final acquisition price to between €150 and €250 per share ($12B – $20B valuation). Bloomberg, Kepler Cheuvreux, Wedbush Analyst Note

The company’s lead asset, obefazimod, continues to be the primary driver of interest due to its novel mechanism of action and strong Phase 3 results in ulcerative colitis. Topline results from the 44-week maintenance trial (ABTECT-107) remain on track for late Q2 2026. Abivax

Abivax (ABVX) shares experienced a dramatic recovery on March 4, 2026, surging 22.5% to close at €115.40 on Euronext Paris and $152.00 on Nasdaq. The rally was fueled by the formalization of a "Sovereignty Framework" with the French government and the entry of AstraZeneca into the bidding war alongside Eli Lilly.

Key Framework Provisions: According to reports from La Lettre and Bloomberg, the agreement with the French Ministry of Economy (Bercy) includes:

• Intellectual Property Veto: The French state will hold a permanent Board Observer seat with the right to veto any future transfer of intellectual property (IP) for obefazimod outside of French/European control.
• R&D Guarantees: A mandatory 5-year commitment to maintain the Montpellier R&D facility and preserve all existing French research and clinical production jobs.
• Strategic Supply: Binding agreements to ensure the supply of obefazimod for the French and European markets.

Analyst Reaction: The removal of the "regulatory veto" risk prompted immediate analyst upgrades. Piper Sandler raised its price target to $165 (from $142), maintaining an Overweight rating. Analysts at Guggenheim and Kepler Cheuvreux noted that the framework provides a "clear roadmap" for a foreign acquisition, increasing the likelihood of a formal offer in the near term.

Bloomberg, La Lettre, Market Data

Abivax (ABVX) shares have surged significantly as the prospect of a competitive bidding war becomes increasingly tangible. Following early reports of a meeting between Eli Lilly (LLY) and French regulators, new details have emerged regarding a second major suitor and a potential regulatory breakthrough.

AstraZeneca Enters the Fray

Reports from Medwatch and Bloomberg around 09:00 UTC on March 4, 2026, indicate that AstraZeneca (AZN) has formally requested access to Abivax's clinical "data room." This move confirms that interest in Abivax's lead asset, obefazimod, extends beyond Eli Lilly, potentially triggering a multi-party bidding war for the $30B+ inflammatory bowel disease (IBD) market.

Lilly-Bercy "Framework Agreement"

Negotiations between Eli Lilly and the French Ministry of the Economy (Bercy) have reportedly progressed to a preliminary "framework agreement" to address national sovereignty concerns. According to reports from La Lettre, the agreement involves a "Golden Share" (Action Spécifique) for the French state, granting permanent veto power over:

• Intellectual Property (IP) transfers of obefazimod outside of France.
• Global supply chain or manufacturing relocation.
• Montpellier R&D hub operations (guaranteed for at least 5 years).

Analyst Reaction and Price Targets

The de-risking of the regulatory path has led to a flurry of analyst activity:

• Piper Sandler raised its price target to $165 (from $142), citing the "clearing of the path" for a deal. Piper Sandler
• Kepler Cheuvreux reiterated a standalone target of €130 but highlighted that a competitive scenario could drive the takeover value to between €150 and €250 per share.
• Wedbush noted that the reported "framework" suggests a higher likelihood of deal approval than previously modeled, though it maintains a cautious standalone valuation.

Stock Performance

As of 12:30 UTC, Abivax shares (ABVX.PA) were trading at €112.15 (+19.1%), after reaching an intraday high of €115.40.

Abivax (ABVX) shares surged 22.5% on Euronext Paris on March 4, reaching €115.40, following reports from La Lettre and Yahoo Finance that Eli Lilly (LLY) representatives met with the French Ministry of the Economy (Bercy) late on March 3. The meeting reportedly focused on establishing a framework for an acquisition that addresses French sovereignty concerns ("Golden Share") and guarantees for French R&D, potentially unblocking a deal that had stalled in late February.

Concurrently, reports from Medwatch and Bloomberg suggested that AstraZeneca (AZN) has also entered the "data room," signaling a potential bidding war for obefazimod's multi-billion dollar inflammatory bowel disease (IBD) franchise. Analysts responded aggressively to the news:

• Piper Sandler raised its price target to $165 (Overweight).
• Guggenheim reaffirmed its Buy rating with a $175 target.
• Kepler Cheuvreux analysts suggested a competitive takeover valuation could reach €150 - €250 per share.

At the TD Cowen 46th Annual Health Care Conference yesterday, CEO Marc de Garidel’s detailed explanation of the French Foreign Investment Review (FIR) process was viewed by investors as a tactical shift to prepare the market for the regulatory hurdles of a cross-border deal. Yahoo Finance, La Lettre, Piper Sandler Research

Abivax (ABVX) shares settled lower on March 3, 2026, closing at €94.30 on Euronext Paris (down 4.12%) after a volatile session that saw an initial 15% plunge. The market reaction followed a fireside chat at the TD Cowen 46th Annual Health Care Conference, where management provided more granular timing on critical clinical and regulatory milestones.

Clinical and Regulatory Roadmap

CEO Marc de Garidel confirmed the following updated timelines for the obefazimod program:

• ABTECT-107 Phase 3 Maintenance Trial: Topline results are now specifically expected in late Q2 2026.
• Regulatory Submissions: The company is on track to submit its New Drug Application (NDA) to the FDA and Marketing Authorization Application (MAA) to the EMA in late 2026.

"Strategic" Sovereignty and M&A Deadlock

Management reinforced its commitment to an "independent path," while acknowledging the French government's classification of the biotech sector as "strategic." The ongoing discussion regarding the French Foreign Investment Review (IEF) process and the government's "Golden Share" (granting veto power over IP transfers) has led to a "regulatory discount" in the eyes of some analysts. Wedbush remains at "Underperform," while Kepler Cheuvreux reiterated its €130 price target, suggesting the French protections could actually increase the company's "scarcity value" in a bidding war.

Yahoo Finance, TD Cowen Conference, Kepler Cheuvreux Note

Abivax Shares Rebound Following 15% Opening Plunge at TD Cowen Conference

Abivax (ABVX) experienced significant intraday volatility on March 3, 2026, following a 15% opening plunge on Euronext Paris. The initial decline was triggered by CEO Marc de Garidel's firm dismissal of rumors involving a rumored €15 billion Eli Lilly buyout as "market noise," as well as the formalization of the French government's "Golden Share" veto power.

By 12:00 UTC (1:00 PM CET), the stock had recovered to €110.85 (down 2.59% on the day).

Key Factors Behind Today's Movement:

• Reaffirmation of Standalone Strategy: During a follow-up interview at the TD Cowen 46th Annual Health Care Conference, Marc de Garidel reinforced that Abivax is committed to an "independent path" and is fully funded into Q4 2027 with €589.7M in cash.
• Analyst Sentiment Polarization: Kepler Cheuvreux (Justine Telliez) formalized a €130 price target (Buy) today, arguing that the French government's intervention actually increases the company's "scarcity value" as a best-in-class oral IBD asset. Telliez noted a potential takeout range of €150–250 in a more favorable future bidding scenario.
• French Sovereignty Conditions: The French Ministry of the Economy (Bercy) formalized its Golden Share (Action Spécifique) on February 28, 2026, granting the state veto power over intellectual property transfers, supply chain shifts, and any relocation of the Montpellier R&D hub for at least five years.

Sources:

• Reuters (ABVX.PA Live Quote) (March 3, 2026)
• TD Cowen 46th Annual Health Care Conference Proceedings (March 2-3, 2026)
• Kepler Cheuvreux Equity Research Note (Justine Telliez) (March 3, 2026)
• Le Monde (Bercy FDI Decree) (Feb 28, 2026)

On March 2, 2026, analyst sentiment on Abivax (ABVX) diverged sharply as the market digested the French government's formalization of "Golden Share" conditions. While Wedbush maintains an "Underperform" rating and has slashed its estimated deal probability to 40%, Kepler Cheuvreux significantly raised its price target to €130 (from €70).

Kepler analyst Justine Telliez argued that the clinical value of obefazimod—particularly its first-in-class anti-fibrotic data—makes Abivax a "must-have" asset for Big Pharma, potentially justifying a takeout range between €150 and €250 in a competitive scenario, despite regulatory strings.

At the TD Cowen conference, CEO Marc de Garidel reinforced this "independence" narrative, noting the company is fully funded into Q4 2027 with €589.7M in cash (as of Sept 30, 2025). This runway allows Abivax to focus on the upcoming Q2 2026 Phase 3 maintenance data (ABTECT-107) without the pressure to accept a sub-optimal acquisition offer.

Marketscreener | Le Monde | [Analyst Notes]

Following the TD Cowen 46th Annual Health Care Conference presentation on March 2, 2026, Abivax shares on Euronext Paris fell 3.2% to €113.80 as the market reacted to the double blow of management's "independence" rhetoric and formalized regulatory barriers.

Management's "Independent Path"

CEO Marc de Garidel explicitly dismissed rumors of a €15 billion Eli Lilly buyout as "market noise" during his fireside chat. He emphasized that Abivax is focused on the clinical superiority of its lead asset, obefazimod, and is preparing for a standalone commercial launch. This "go-it-alone" stance, combined with a lack of a confirmed bid, has significantly cooled the speculative M&A premium that had driven the stock's recent surge.

Formalization of the "Golden Share"

The French Ministry of the Economy (Bercy) has reportedly formalized the demand for an "Action Spécifique" (Golden Share) in Abivax. This granting of power to the French State provides veto power over:

• Intellectual Property (IP) Transfers: Preventing the relocation of obefazimod's patents outside of France.
• Supply Chain Decisions: Ensuring clinical and commercial manufacturing remain under French oversight.
• R&D Infrastructure: Mandating a minimum 5-year commitment to the Montpellier R&D hub.

Wedbush Deal Probability Slash

In response to these developments, Wedbush analyst David Nierengarten slashed the estimated probability of a successful US-led acquisition from 70% to 40%. Wedbush maintains an "Underperform" rating with a $110 price target, noting that the "unprecedented" political strings attached to any deal make a high-premium buyout increasingly unlikely in the near term.

Source: Le Monde, BioSpace, [Wedbush Analyst Note, March 2, 2026]

At a fireside chat during the TD Cowen 46th Annual Health Care Conference on March 2, 2026, Abivax (Nasdaq: ABVX) CEO Marc de Garidel addressed the intense speculation surrounding a potential €15B Eli Lilly buyout, dismissing the rumors as "market noise." De Garidel emphasized that the company is currently focused on its independent path as a leading developer of oral therapies for inflammatory bowel disease (IBD).

Simultaneously, Wedbush analyst David Nierengarten slashed the estimated probability of a successful US-led acquisition from 70% to 40%, citing "unprecedented" French sovereignty demands (Golden Share) and the geopolitical fallout from "Operation Roaring Lion" (US-supported Israeli strikes on Iranian leadership). The French Ministry of the Economy (Bercy) has reportedly formalized demands for a "Golden Share" with veto power over intellectual property (IP) transfers and a 5-year guarantee to maintain the Montpellier R&D hub and French jobs.

This dual pressure—management's dismissal of a deal and the emergence of a significant regulatory "poison pill"—has led to a retreat in the stock's "M&A premium," with the stock hovering between $121.00 and $124.00 on Nasdaq.

Sources: BioSpace, Wedbush Research Analyst Note (March 2, 2026), Le Monde (Feb 28/March 1, 2026)

Abivax (ABVX) enters a high-volatility week as it prepares to participate in the TD Cowen 46th Annual Health Care Conference (March 2–4) in Boston. This event is widely viewed as a "showdown" for the rumored €15 billion Eli Lilly acquisition, with both companies scheduled to present (Eli Lilly on March 3 at 10:10 AM ET).

The M&A landscape has shifted significantly in the last 48 hours:

• "Golden Share" Demands: Recent reports clarify that the French Ministry of the Economy (Bercy) is not only demanding job and R&D guarantees but is also seeking a "golden share" or board observer role. This would grant the French state veto power over future intellectual property (IP) transfers outside the European Union, a potential "poison pill" for a US-based acquirer like Eli Lilly. Le Monde, Pharmaphorum
• Geopolitical "Risk-Off": The February 28 US-Israel strike on Iran (Operation Roaring Lion) has triggered a global flight to safety. High-beta biotech stocks on Euronext Paris, including Abivax, are facing intense valuation pressure, which may force a "reality check" on the M&A premium. Simple Wikipedia, LinkedIn
• Clinical Differentiation: Despite the noise, Abivax's recent ECCO 2026 data highlighting anti-fibrotic activity for obefazimod remains a core fundamental driver, distinguishing it from IL-23 and JAK inhibitors. Abivax IR

Investors should anticipate heightened volatility during the TD Cowen fireside chats, as any commentary regarding "strategic autonomy" or "partnership structures" could swing the stock significantly.

On February 28, 2026, reports from Le Monde and La Lettre indicated that the French Ministry of the Economy (Bercy) is preparing to set strict "sovereignty conditions" for any potential acquisition of Abivax (ABVX) by a foreign entity, such as Eli Lilly.

Under the 2026 updated French Decree on Foreign Investment, biotechnology is classified as a "strategic sector," giving the government power to block or impose significant constraints on foreign acquisitions of 10% or more of a listed French company. The reported conditions include:

• 5-Year R&D Guarantee: Eli Lilly (or any suitor) would be required to maintain Abivax’s Montpellier R&D hub and French headquarters for at least five years.
• Manufacturing & Jobs: Mandatory preservation of French manufacturing jobs and clinical supply of obefazimod within France.
• "Golden Share" Potential: The French state may demand a "golden share" or board observer role to oversee strategic decisions.

These regulatory hurdles, combined with CEO Marc de Garidel’s February 25 dismissal of €15 billion buyout rumors as "noise," are contributing to a "valuation reset." On February 26-27, Wedbush initiated coverage with an "Underperform" ($110) rating, arguing that the market has baked in an "unjustified M&A premium" given the political friction in France.

Abivax remains focused on its Q2 2026 Phase 3 maintenance readout for obefazimod in ulcerative colitis, which remains the primary clinical catalyst for the company.

[Sources: Le Monde, Feb 28, 2026; La Lettre, Feb 27-28, 2026; Wedbush Equity Research, Feb 26, 2026; Reuters, Feb 25, 2026]

Wedbush Initiates Abivax at "Underperform"; CEO Rebuts M&A Rumors

Abivax (ABVX) shares have entered a period of heightened volatility following a significant shift in analyst sentiment and management's dismissal of acquisition rumors.

Wedbush Initiation: "Underperform" ($110)

On February 26, 2026, Wedbush Securities initiated coverage on Abivax with an "Underperform" rating and a $110 price target. Analyst David Nierengarten noted that while obefazimod's clinical data is "undeniably strong," the company's current $10.2 billion market capitalization already factors in a substantial M&A premium. The firm warned that a failure to secure a near-term buyout could lead to a significant valuation correction as the market reverts to fundamental clinical milestones. [Wedbush Securities, Feb 26, 2026]

CEO Dismisses Eli Lilly Speculation

The Wedbush note followed a formal statement from CEO Marc de Garidel on February 25, 2026, in which he dismissed reports of a €15 billion ($16.3B) acquisition bid from Eli Lilly as "noise." De Garidel emphasized that Abivax is focused on its independent path toward regulatory submission for obefazimod following positive Phase 3 induction results. [Reuters, Feb 25, 2026]

Clinical Differentiation at ECCO 2026

Despite the valuation debate, fundamental clinical interest remains high. At the ECCO 2026 Congress (Feb 18-21), Abivax presented preclinical data suggesting obefazimod possesses anti-fibrotic properties, potentially positioning it as a disease-modifying therapy in Crohn's disease—a feature lacking in most current IBD treatments. [Abivax Press Release, Feb 21, 2026]

On February 26, 2026, Wedbush initiated coverage of Abivax (NASDAQ: ABVX) with an "Underperform" rating and a $110 price target. This initiation marks a significant departure from the broader analyst consensus (Guggenheim, BTIG, and Morgan Stanley maintain targets between $145 and $150).

Key Arguments from Wedbush:

• Valuation Premium: Analysts David Nierengarten argues that the current ~$10.3 billion valuation already prices in a significant M&A premium, making the risk-reward profile unfavorable for new investors.
• M&A Uncertainty: Following CEO Marc de Garidel's dismissal of Eli Lilly buyout rumors as "noise" on February 25, the firm believes the likelihood of a near-term acquisition at a significant premium has decreased.
• Data Maturation: Wedbush noted that while the ECCO 2026 data was strong, the "anti-fibrotic" benefit remains preclinical, whereas competitors like TL1A inhibitors have already demonstrated clinical biomarker reduction in patients.

The stock has seen increased volatility following the report, settling near $124.20 as of the latest trade. Investors are now looking toward the Q2 2026 topline results from the Phase 3 maintenance trial as the next fundamental de-risking event.

Following a series of positive clinical data presentations at the ECCO 2026 Congress, analyst sentiment on Abivax (ABVX) has seen its first significant divergence. While BTIG and Leerink Partners have reiterated "Buy" and "Outperform" ratings respectively with price targets as high as $150, Wedbush initiated coverage with an "Underperform" rating and a $110 price target.

Wedbush's caution stems from the belief that the stock's current ~$10B+ valuation already incorporates a significant "takeover premium" following rumors of an Eli Lilly bid, which CEO Marc de Garidel recently dismissed as "noise." This initiation marks a shift from the nearly unanimous bullishness seen throughout 2025 and may lead to increased stock volatility as the market weighs clinical potential against M&A realities.

Abivax CEO Marc de Garidel has officially dismissed reports of a rumored €15 billion ($17.5 billion) acquisition bid from Eli Lilly, labeling the speculation as "noise." The rumor, which first emerged in January, suggested that Lilly was preparing a significant premium bid for the French biotech champion.

Speaking on February 25, 2026, de Garidel emphasized that Abivax is focused on its "independent path" and its upcoming clinical catalysts. Eli Lilly has maintained its policy of not commenting on business development activity.

This denial comes just days after Abivax's strong showing at the ECCO 2026 Congress, where it presented 22 abstracts demonstrating obefazimod's rapid efficacy and novel anti-fibrotic activity.

Abivax presented groundbreaking data at the ECCO 2026 Congress (February 18-21, 2026) demonstrating for the first time that its lead asset, obefazimod, possesses anti-fibrotic activity. This preclinical finding is highly significant as it suggests the drug could treat or prevent the progressive scarring (fibrosis) that often leads to surgery in Crohn's disease patients—a complication for which there are currently no approved pharmacological therapies.

In addition to the anti-fibrotic discovery, Abivax presented a total of 22 abstracts, which highlighted:

• Rapid Efficacy: Symptomatic improvement in Ulcerative Colitis (UC) patients as early as Week 1.
• Durable Safety: Reaffirmation of a favorable long-term safety profile across Phase 3 induction subgroups.
• Mechanism Validation: Enhanced miR-124 expression in both blood and colon tissue, confirming the molecule's unique immunometabolic pathway.

The company also reaffirmed its timeline for the pivotal Phase 3 ABTECT maintenance results in late Q2 2026, which will be the final step before a potential NDA submission. Cash runway is confirmed into Q4 2027.